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Viral double-stranded RNA (dsRNA) is a ubiquitous in-
tracellular “alert signal” used by cells to detect vi-
ral infection and to mount anti-viral responses. DsRNA
triggers a rapid (complete within 2–4 h) apoptosis in
the highly-susceptible HeLa cell line. Here, we demon-
strate that the apical event in this apoptotic cas-
cade is the activation of procaspase 8. Downstream
of caspase 8, the apoptotic signaling cascade bifur-
cates into a mitochondria-independent caspase 8/cas-
pase 3 arm and a mitochondria-dependent, caspase
8/Bid/Bax/Bak/cytochrome c arm. Both arms impinge
upon, and activate, procaspase 9 via two different cleav-
age sites within the procaspase 9 molecule (D330 and
D315, respectively). This is the first in vivo demonstration
that the “effector” caspase 3 plays an “initiator” role in the
regulation of caspase 9. The dsRNA-induced apoptosis is
potentiated by the inhibition of protein synthesis, whose
role is to accelerate the execution of all apoptosis steps
downstream of, and including, the activation of caspase
8. Thus, efficient apoptosis in response to viral dsRNA
results from the co-operation of the two major apical cas-
pases (8 and 9) and the dsRNA-activated protein kinase R
(PKR)/ribonuclease L (RNase L) system that is essential
for the inhibition of protein synthesis in response to viral
infection.
Keywords: apoptosis; caspases; double-stranded RNA;
encephalomyocarditis virus
Introduction
Eukaryotic cells “sense” the need to mount specific re-
sponses to viral infections by recognizing the appearance
of viral intermediates that are absent in naı¨ve, uninfected,
cells. A property exclusively restricted to viruses is their
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ability to produce, intracellularly, copious amounts of
RNA species forming double-stranded helices [reviewed
in ref.1]. Binding of dsRNA to intracellular sensor(s) leads
to an antiviral response that is comprised of two impor-
tant components: a productive/alarming response coordi-
nated by the activation of protein kinases that lead to the
transcriptional activation of interferons, cytokines, and
chemokines2–4 and a destructive/suicidal response that re-
sults from engagement of an apoptotic program.5–10 The
importance of apoptosis as an effective antiviral strategy
is underscored by the plethora of apoptosis-suppressing
proteins encoded by viral genomes [reviewed in refs11,12].
Furthermore, genetic evidence from mice13 demonstrates
that inhibition of apoptosis by the virus is critical for the
virulence of encephalomyocarditis virus (EMCV), a picor-
navirus that is lethal to infected mice.
Extensive investigations into the mechanisms of
apoptosis14 have revealed the existence of intrinsic and
extrinsic apoptosis-initiating pathways [for reviews on
apoptosis, see refs15–21]. In the extrinsic pathway, special-
ized proteinaceous extracellular death ligands (e.g., FasL,
TNF-α) bind to cognate death receptors (e.g., Fas, TNF-
R1, respectively) [reviewed in ref.22]. The cytoplasmic
portions of death receptors recruit “adaptor” proteins such
as the Fas-associated protein with death domain (FADD,
also known as MORT1).23,24 The recruitment of FADD
leads to the subsequent recruitment of a dormant pro-
tease, referred to as procaspase 8, FLICE, or MACH.25,26
The resulting multiprotein complex containing FasL, Fas,
FADD, and procaspase 8 is known as the death-inducing
signaling complex (DISC).27 The increased local concen-
tration within the DISC of the procaspase 8 allows for
its spontaneous autocatalytic cleavage and activation by
“induced proximity”.28
In the intrinsic apoptotic pathway, various signals (usu-
ally generated by cellular stress) converge on, and com-
promise, the capability of the outer mitochondrial mem-
brane to remain impermeable to cytochrome c [reviewed
in refs29−31]. Once released from mitochondria into the
cytosol, cytochrome c becomes a positive regulator of the
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apoptosome,32,33 a sevenmeric complex of the protein
APAF1 (apoptotic protease-activating factor 1) bound to
another dormant protease referred to as procaspase 9, ICE-
LAP6, or Mch6.34,35 Similar to procaspase 8, the “induced
proximity” of procaspase 9 triggers its own autocatalytic
processing and activation.33,36
Caspases 8 and 9 are referred to as “initiator” or “api-
cal” caspases [reviewed in refs37,38]. Initiator caspases ex-
ert their functions predominantly by activating (through
targeted proteolysis) downstream caspases with (referred
to also as “effector”, or “executioner”, caspases). These
include caspases 3, 6, 7, and, possibly, 14.37,38 In gen-
eral, all procaspases undergo activation via two succes-
sive proteolytic events: first between the large and the
small subunits and then between the large subunit and the
prodomain.37,38 The active tetrameric enzymes are com-
posed of two dimers, each dimer consisting of one cleaved
large and one cleaved small subunit.37,38 The proper func-
tioning of the active caspase at a different cellular location
may require the cleavage of the prodomain and release
of the active enzyme from its “anchor”. Once activated
by the initiator caspases, effector caspases dismantle the
apoptotic cell by systematically cleaving more than 100
cytoplasmic and nuclear substrates, thus interfering with
virtually every cellular function. Based on the consensus
cleavage sequence DEVD (the arrow represents the cleav-
age occurring C-terminally of the aspartic acid residue in
P1 position) for the effector caspases 3 and 7 found in the
abundant caspase substrate poly(ADP)ribose polymerase
(PARP), these two caspases are sometimes referred to as
DEVDases.37,38
The activation of procaspase 8 can activate the apop-
totic program both by direct cleavage of procaspase 3
and by provoking the release of cytochrome c from mi-
tochondria. The mitochondrial arm activated by caspase
8 is initiated by the cleavage of Bid, a free cytosolic
protein, to a ∼15 kDa truncated form, tBid.39,40 tBid
translocates to mitochondria39,40 and, in collaboration
with either Bax or Bak (two pro-apoptotic Bcl-2 fam-
ily members), triggers the release of cytochrome c from
mitochondria.41 In non-apoptotic cells, Bax is a cytoso-
lic protein, which, in response to cleavage of Bid, inserts
into the outer mitochondrial membrane where it forms an
oligomeric channel of poorly understood conductance.42
Unlike Bax, Bak is constitutively associated with mito-
chondrial membranes.43–46 Upon stimulation with pro-
apoptotic agents, Bak is “activated” (also via oligomer-
ization and channel formation) and its association with
mitochondrial membranes is altered, although the mech-
anisms of this alteration are poorly understood [43–45,47
this work].
In this work, we employed HeLa cells to dissect the
apoptotic mechanisms that mediate the activation of cas-
pase 9 in response to dsRNA. We demonstrate that cas-
pase 8 (previously implicated in the initiation of dsRNA-
induced apoptosis)5,48 is positioned upstream of caspase 9
in the genesis of the dsRNA-triggered apoptotic signal.
Unexpectedly, we observed that the caspase 8-activated
DEVDase caspase 3 appears to process caspase 9 at aspar-
tic acid residue D330 in a way that kinetically precedes
the cytochrome c-stimulated autocatalytic processing of
caspase 9 at aspartic acid residue D315. To our knowledge,
this is the first in vivo demonstration that the “effector”
caspase 3 plays an “initiator” role in the regulation of cas-
pase 9. We demonstrate next that the apoptotic function
of the dsRNA-induced inhibition of protein synthesis is
to potentiate the apoptotic signal downstream of, and in-
cluding, the activation of caspase 8.
Materials and methods
Chemicals
LipofectinTM Reagent was from Invitrogen Life Technolo-
gies. Synthetic nucleic acids were from either Midland
Certified Reagent Co (polyinosinic.polycytidylic acid,
pI.pC; polyinosinic acid, pI; polycytidylic acid, pC), Cal-
biochem (pI.pC), or Pharmacia & Upjohn (p[d(IC)]). All
synthetic nucleic acids were stored at−20◦C as 10 mg/ml
stock solution in double-distilled deionized water. All cas-
pase inhibitors (Calbiochem) were stored at −20◦C as
25 mM stock solutions in DMSO. All commonly used
chemicals and cycloheximide (CHX) were from Sigma
Chemical Company. CHX was dissolved freshly before
use in double-distilled deionized water.
Cells and plasmids
Subconfluent cells grown on 100-mm or 60-mm tissue
culture plates were used for experiments. HeLa and
MCF-7 cells were maintained in Dulbecco modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (HyClone) and antibiotics. Human full
length caspase 3 cDNA was subcloned into a PCR3
expression vector.
Lipofectin-mediated delivery of pI.pC
Per each milliliter final volume (4/4) of Lipofectin mix-
ture, an initial concentrated mixture (containing Lipo-
fectin and pI.pC) was prepared in 1/4 of the final volume
(250 µl). To this end, 10 µl Lipofectin (1 mg/ml) were
added to serum- and antibiotic-free DMEM, mixed, and
the desired amount of pI.pC was added (in a volume of
250 µl). This mixture was left for 10 min at room tem-
perature. Finally, the remaining 3/4 of the final volume
(750 µl) of serum- and antibiotic-free DMEM were added.
Before the application of the Lipofectin/pI.pC mixtures,
the cells were washed once with serum- and antibiotic-free
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DMEM. The same procedure was applied for the delivery
of all other synthetic nucleic acids.
Preparation of cell lysates for
immunoblot analysis
To avoid potential post-lysis modifications or degradation
of proteins of interest, the cells were harvested by a direct
lysis in 2×DS-PAGE sample-loading buffer, followed by
heat denaturation at 95◦C for 5 min and a mechanical or
ultrasonic shearing. Typically, the detached (dead) cells
were sedimented from the growth medium by centrifu-
gation, lysed in 2×DS-PAGE sample-loading buffer, and
combined with the cell lysates from adherent cells. Cell
lysates were stored at −70◦C.
Antibodies and immunoblot analyses
The antibodies against PARP (H-250), cytochrome
c (H-104), Bax (N-20, HRP-conjugated), and Bak
(G-23) were from Santa Cruz Biotechnologies. The an-
tibodies against caspase 3 (65906E; discontinued due to
death of producing animal) and caspase 7 (clone B94-
1) were from Pharmingen/BD Biosciences. The antibod-
ies against caspase 8 (1C12) and caspase 9 (p37-specific,
p35-specific, and full length/p37/p35-specific) were from
Cell Signaling Technology. The antibody against Bid (rab-
bit, polyclonal) was from Biosource International. The
Fas-activating antibody (clone CH11) was from Upstate
Biotechnology. The electrophoretic separation of pro-
teins in SDS-PAGE and electrotransfer onto PVDF mem-
brane (Millipore) were performed using standard pro-
cedures. Immunoprobing with specific antibodies and
enhanced chemiluminescent detection (DuPont NEN Re-
search Products) were performed following the instruc-
tions of the respective manufacturers.
Analysis of the subcellular distribution of Bid,
Bax, Bak, and cytochrome c
Cytosolic and organellar fractions were prepared and ana-
lyzed as previously described in ref.6 Briefly, control and
treated cells were harvested by scraping directly in the
medium, sedimented, washed once in ice-cold PBS and
once in isotonic sucrose buffer (SU buffer: 250 mM su-
crose, 10 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1
mM EDTA, 1 mM EGTA, pH 7.1) and then permeabi-
lized for 1 min at room temperature (RT) in SU buffer
containing 0.025% digitonin and CompleteTM protease
inhibitor cocktail. The efficiency of permeabilization was
nearly 100% as measured by trypan blue exclusion. Af-
ter sedimenting the cellular pellet, the supernatant was
designated “cytosol(ic fraction)”. The pellet of permeabi-
lized cells was resuspended in SU buffer containing 0.5%
Triton X-100 and CompleteTM Protease Inhibitor Cock-
tail and kept for 10 min on ice, after which the Triton
X-100-soluble and -insoluble fractions were separated
by centrifugation. All three fractions were resolved in
15% SDS-PAGE, transferred onto PVDF membrane and
probed with appropriate antibodies.
Infection of cells with EMCV
Approximately 3 × 106 HeLa cells were infected with
EMCV (∼100 pfu per cell) in 2 ml of serum-free medium
for 1 h, after which time the excess of the virus was re-
moved by extensive washing of the cells with serum-free
medium. The cells were further incubated in serum-free
medium.
Results
DsRNA triggers a rapid apoptotic
response in HeLa cells
To determine the cytotoxicity of dsRNA in HeLa cells,
we treated the cells with the synthetic dsRNA polyi-
nosinic.polycytidylic acid (pI.pC, hereafter referred to
as dsRNA) in the presence of LipofectinTM reagent to
ensure efficient internalization (see Experimental Proce-
dures) and monitored, in immunoblot analyses, the cleav-
age (activation) of caspases 8, 9, 3, and 7 over a period of
time from 1 h to 6 h post treatment. The processing of pro-
caspase 8 was assessed employing an antibody recognizing
an epitope within the large subunit of caspase 8. Within
2 h post treatment, dsRNA triggered efficiently the pro-
cessing of procaspase 8 to two fragments running in SDS-
PAGE as a doublet of ∼41–43 kDa (Figure 1, panel A,
lane 4). This doublet (hereafter referred to, collectively, as
p43/p41) represents the large subunit of caspase 8 with an
uncleaved prodomain and it is likely to result from one of
the following three reasons. First, the doublet may be the
product of the utilization of two alternative cleavage sites
(VETD374 and LEMD384) between the large and the small
subunits.37 Second, the two fragments may be the result
of the cleavage of two different splice forms of procaspase
8 (MACHα1 and MACHα2)25 at the same cleavage site
(either VETD374 or LEMD384). In support of the latter
notion, a better resolution of procaspase 8 in SDS-PAGE
(Figure 6) demonstrates that HeLa cells express indeed
two bands with procaspase 8 immunoreactivity. Finally,
a combination of both expression of two splice forms of
the procaspase 8 and utilization of alternative cleavage
sites may explain the appearance of the doublet p43/p41.
With the antibody employed, neither of these three possi-
bilities can be ruled out. Further cleavage of the p43/p41
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Figure 1. DsRNA triggers rapid apoptosis in HeLa cells. The cells
were treated with Lipofectin alone (Co, control) or with Lipofectin
with pI.pC (dsRNA; 3 µg/ml) as described in Experimental Pro-
cedures. At the indicated times after the treatment, the cells were
harvested and processed for immunoblot analyses as described
in Experimental Procedures. Immunoblot detections of caspases
8 (C-8, panel A), 9 (C-9, panels B and C), 3 (C-3, panel D), and
7 (C-7, panels E and F) and of PARP (panel G) were performed
using appropriate antibodies as described in Results and Exper-
imental Procedures. Here, as well as in Figure 6, the detection
of p37 and p35 fragments of caspase 9 was performed using an-
tibodies specific for the respective fragments (see Experimental
Procedures). Everywhere else, procaspase 9, p37, and p35 were
detected using an antibody recognizing all three polypeptides (see
Experimental Procedures). See text for the description of the de-
tected fragments of individual caspases.
fragments of caspase 8 to the fully-processed p18 large
subunit was only weakly detectable at 2 h, but it inten-
sified dramatically between 2 and 4 h after the addition
of dsRNA, reaching an apparent steady-state plateau be-
tween 4 and 6 h post treatment (Figure 1, panel A, lanes
4–6). The small (p10) subunit of caspase 8 cannot be de-
tected with the antibody employed. The mechanism of
activation of caspase 8 by intracellular accumulation of
dsRNA is addressed elsewhere (Iordanov et al., submit-
ted).
The activation of procaspase 9 was assessed using two
antibodies that discriminate between the two alternative
fragments of caspase 9 resulting from different mecha-
nisms of activation (see below). The cleavage of procaspase
9 at DQLD330 to generate a p37 fragment [i.e. the large
subunit with an uncleaved prodomain]36 was well de-
tectable as early as 2 h post treatment with dsRNA and the
steady-state levels of p37 did not intensify detectably be-
tween 2 and 6 h (Figure 1, panel B, lanes 4–6). In contrast,
the appearance of p35 fragment of caspase 9 [cleavage at
PEPD315]36 was delayed and reached stable steady-state
levels between 2 and 4 h post treatment (Figure 1, panel C,
lanes 4–6). Thus, the time course of appearance of the p37
and p35 fragments of caspase 9 provided support to the
notion that during the response of HeLa cells to dsRNA
procaspase 9 is activated first via cleavage by the effec-
tor caspase 3 at DQLD330 36 and later via autocatalytic
processing at PEPD315.36 Consistent with the findings of
Srinivasula et al.,36 the prodomain of caspase 9 was not
proteolytically removed from the p37 and p35 fragments
(see Figure 8). Procaspase 3 was processed in response to
dsRNA first by the cleavage of the procaspase at IETD175
to form a short-lived intermediate p20 (large subinit with
an uncleaved prodomain 37,49,50) detectable only at 2 h
post dsRNA (Figure 1, panel D, lane 4). The p20 frag-
ment was further processed to produce two forms of the
large subunit, p19 and p17, resulting from the successive
(auto)cleavages at NSVD9 and ESMD28 37,49,50 (Figure 1,
panel D, lanes 4–6). Procaspase 7 was processed through
a proteolytic intermediate of unclear identity (Figure 1,
panels E and F, lanes 4–6, arrow) that matured, eventually,
to the p20 large subunit. To monitor the overall degree of
apoptosis in the dsRNA-treated HeLa cells, we assessed
the proteolytic cleavage of PARP. Strikingly, the cleav-
age of PARP was completed between 2 and 4 h after the
treatment with dsRNA (Figure 1, panel G, lanes 4–6),
suggesting that a complete course of apoptosis can be ex-
ecuted within 4 h of the treatment of HeLa cells with
dsRNA.
In order to determine whether the results shown in
Figure 1 were due indeed to the double-stranded RNA
nature of the introduced pI.pC, we performed identical
experiments with the exception that instead of pI.pC, we
employed ssRNA (either pI or pC) as well as dsDNA
(p[d(IC)]). Neither ssRNA nor dsDNA displayed any de-
tectable toxicity for up to 48 h, after which time the
experiment was terminated (not shown). We concluded,
therefore, that dsRNA (but not ssRNA or dsDNA) is ex-
clusively capable of triggering rapid apoptosis in HeLa
cells.
A prominent role for caspase 8 in the initiation
of the rapid dsRNA-induced apoptosis
To elucidate the order of caspase activation in dsRNA-
induced apoptosis, we employed general or specific in-
hibitors of caspase activities: zVADfmk, a pan-caspase
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inhibitor, zDEVDfmk, an inhibitor of effector caspases
(DEVDases, such as caspases 3 and 7), zIETDfmk, an
inhibitor of caspase 8, and zLEHDfmk, an inhibitor of
caspase 9.51,52 HeLa cells were treated with dsRNA for
2 or 4 h in the absence or in the presence of a 30 min
pretreatment with the respective caspase inhibitor (50
µM each) and the proteolytic processing of the initia-
tor caspases 8 and 9, and of the effector caspases 3 and
7 was monitored in immunoblot analyses. The overall
effect of caspase inhibition by each inhibitor was deter-
mined by the degree of cleavage of PARP. The outcome
of these analyses is presented in Figure 2. The pancaspase
inhibitor zVADfmk potently inhibited the activation by
dsRNA of all caspases studied and prevented almost com-
pletely the processing of PARP (Figure 2A, compare lanes
4 and 10 to lanes 5 and 11). At the concentration used,
the caspase 8 inhibitor zIETDfmk strongly inhibited and
delayed (but did not completely abolish) the first step
on processing of procaspase 8, namely the autocatalytic
cleavage at VETD374 (and/or LEMD384) to produce the
p43/p41 fragments (Figure 2A, compare lanes 4 and 10
to lanes 6 and 12). Interestingly, zIETDfmk was almost
as efficient in inhibiting the dsRNA-induced processing
of procaspase 9 (shown in Figure 2A, lanes 4 and 10)
as the pancaspase inhibitor zVADfmk (Figure 2A, com-
pare lanes 5 and 11 to lanes 6 and 12). This result, to-
gether with the temporal sequence of appearance of the
two caspase 9 fragments (i.e., the appearance of the caspase
3-processed p37 first and of the caspase 9-processed p35
second; Figure 2A, compare lanes 4 and 16 to lanes 10 and
22), strongly supports the notion that caspase 8-activated
caspase 3 is instrumental the activation of caspase 9 in re-
sponse to dsRNA. zIETDfmk suppressed (2 h, Figure 2A,
compare lanes 4 and 6) and delayed (4 h, Figure 2A,
compare lanes 10 and 12) the processing of procaspase
3. Thus, at 4 h, the processing of caspase 3 was arrested
by zIETDfmk at the level of the p20 intermediate frag-
ment (Figure 2A, compare lanes 10 and 12). zIETDfmk
affected the dsRNA-induced processing of procaspase 7
similarly to its effects on procaspase 3 (Figure 2A). Fi-
nally, zIETDfmk substantially delayed, but did not pre-
vent the processing of PARP (Figure 2A, compare lanes
4 and 10 to lanes 6 and 12). As expected, the caspase 9
inhibitor zLEHDfmk strongly suppressed the appearance
of the autocatalytically-produced p35 fragment, but was
much less effective in suppressing the processing of pro-
caspase 9 to the p37 fragment by caspase 3 (Figure 2B,
compare lanes 16 and 22 to lanes 18 and 24). Similar to
zIETDfmk, but significantly less efficiently, zLEHDfmk
appeared to inhibit the last step of the processing of pro-
caspase 3, namely, the conversion of p20 to the p19 and
p17 fragments (Figure 2B, compare lanes 16 and 22 to
lanes 18 and 24). Consistent with the inefficient abil-
ity of zLEHDfmk to block the processing of caspase 3,
the inhibitor was also inefficient in blocking the cleav-
Figure 2. Inhibition of dsRNA-induced apoptosis by caspase-
specific peptide inhibitors. (A) and (B) HeLa cells were treated,
for the indicated times, as in Figure 1, except for the 30 min
pre-incubation of the cells, where indicated, with various cas-
pase inhibitors. Immunoblot detections of caspases 8, 9, 3, and
7 and of PARP are presented. See text for the description of the
detected fragments of individual caspases. “-”, no pretreatment
with inhibitors or treatment with dsRNA; VAD, zVADfmk; IETD,
zIETDfmk; DEVD, zDEVDfmk; LEHD, zLEHDfmk.
age of PARP (Figure 2B, compare lanes 16 and 22 to
lanes 18 and 24). The inhibitor of “DEVDases” (caspases
3 and 7) zDEVDfmk displayed an equal to zVADfmk
ability to block the processing of procaspase 9 at both
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the DQLD330 site (p37 fragment) and the PEPD315 site
(p35 fragment) (Figure 2, compare lanes 4, 5, 10, 11,
16, 17, 22, and 23). The specificity of this inhibitor is
demonstrated by the fact that, at the level of processing of
procaspase 3, zDEVDfmk blocked the autocatalytic pro-
cessing of p20 to p19/p17, but failed completely to in-
hibit the formation of p20 in the first place (Figure 2B,
compare lanes 16 and 22 to lanes 17 and 23). Consis-
tent with the inhibition of DEVDases by zDEVDfmk,
the dsRNA-induced proteolytic cleavage of PARP was
strongly suppressed by zDEVDfmk (Figure 2B, compare
lanes 16 and 22 to lanes 17 and 23). Interestingly, all
four caspase inhibitors used proved equally efficient in
blocking the final processing of the p43/p41 fragments
of caspase 8 to the mature p18 large subunit (Figure 2,
compare lanes 4 and 10 to lanes 5, 6, 11, 12, 17, 18, 23,
24).
The dsRNA-induced processing of procaspase 9
to p37 (but not to p35) requires caspase 3
To determine whether the dsRNA-induced cleavage of
procaspase 9 at DQLD330 is mediated exclusively by cas-
pase 3 (or, alternatively, could be executed by another DE-
VDase, such as caspase 7), we employed the human breast
carcinoma cell line MCF-7, which has been previously re-
ported to lack detectable levels of caspase 3 protein.53 We
confirmed that MCF-7 cells express detectable levels of
caspase 7, but are indeed devoid of caspase 3 (Figure 3A,
panels A3 and A4). When challenged with dsRNA, MCF-
7 cells demonstrated a processing of procaspase 8 that was
identical (albeit delayed) in the nature of the detected frag-
ments to the processing of caspase 8 in dsRNA-treated
HeLa cells (Figure 3A, panel A1, lanes 5–8). However,
only the p35, but not the p37, fragment of caspase 9
was detectable in the dsRNA-treated MCF-7 cells (Fig-
ure 3A, panel A2, lanes 5–8). The transient overexpres-
sion of full length caspase 3 in MCF-7 cells proved to be
cytotoxic and precluded the possibility of studying the
effects of restoring caspase 3 expression on the dsRNA-
induced apoptosis. However, upon transfection of caspase
3 in MCF-7 cells (Figure 3B, panel B1, lanes 3 and 4), a
clear increase in the appearance of p37 fragment of cas-
pase 9 was observed (Figure 3B, panel B3, lanes 3 and 4),
consistent with the notion that caspase 3 is indeed capable
of cleaving procaspase 9 at DQLD330. The fact that some
constitutive appearance of the p37 fragment of caspase 9
was observed in the absence of transfected caspase 3 (Fig-
ure 3B, panel B3, lanes 1 and 2) suggests that caspase 3
is not the only caspase capable of cleaving the DQLD330
site of caspase 9. Taken together, the results presented in
Figure 3A and B strongly support the notion that caspase
3 is a major DEVDase responsible for the processing of
caspase 9 at the DQLD330 cleavage site.
Figure 3. Absence of detectable levels of caspase 3 and reduced
p37 caspase 9 fragment in MCF-7 cells. (A) MCF-7 cells were
treated as HeLa cells were in Figure 1. Immunoblot detections of
caspases 8 (C-8, panel A1), 9 (C-9, panel A2), 3 (C-3, panel A3),
and 7 (C-7, panel A4) and of PARP (panel A5) are presented.
See text for the description of the detected fragments of individual
caspases. (B) MCF-7 cells were transfected in duplicates with
either an empty PCR3 expression vector (lanes 1 and 2) or PCR3-
caspase 3 construct. Twenty for hour later the cells were harvested
and processed for immunoblot analyses of caspase 3 (panel B1),
procaspase 9 (panel B2), p37 caspase 9 (panel B3), and p35
caspase 9 (panel B4).
Mobilization of Bid, Bax, and Bak, and release
of cytochrome c from mitochondria in response
to dsRNA
To determine the mechanism of activation of caspase 9
in dsRNA-treated HeLa cells, we investigated the status
of Bid, Bax, Bak, and cytochrome c in dsRNA-treated
HeLa cells. To this end, we fractionated cells into 3 frac-
tions: (i) a cytosolic fraction containing soluble proteins
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Figure 4. Mobilization of Bid, Bax, and Bak, and release of cytochrome c from mitochondria in response to dsRNA. (A and B) Where
indicated, HeLa cells were treated for 3 h (A) or 6 h (B) with CHX (25 µg/ml), CH11 (0.5 µg/ml), dsRNA (pI.pC; 3 µg/ml), or the indicated
combinations thereof. The cells were processed as described in Experimental Procedures to yield three fractions as follows: cytosol
(lanes 1, 4, 7, 10, 13, and 16), non-cytosolic (organellar) material soluble in Triton X-100 [“S” (supernatant), lanes 2, 5, 8, 11, 14, and
17], and non-cytosolic (organellar) material resistant to solubilization in Triton X-100 [“P” (pellet), lanes 3, 6, 9, 12, 15, 18). Immunoblot
analyses depicting the appearance of Bid, Bax, Bak, and cytochrome c, in each fraction are presented. The membranes were re-probed
for caspase 8 and PARP to monitor for the overall degree of apoptosis after each treatment. Results are interpreted in the text.
(A)
(B)
(represented in Figure 4 by lanes 1, 4, 7, 10, 13, and
16), (ii) a fraction containing proteins that are associ-
ated with organellar, nuclear, or plasma membranes but
are solubilized in Triton X-100 (represented in Figure 4
by lanes 2, 5, 8, 11, 14, and 17), and (iii) a fraction
of intraorganellar proteins that are resistant to solubi-
lization with Triton X-100 (represented in Figure 4 by
lanes 3, 6, 9, 12, 15, and 18; see Experimental Proce-
dures). In untreated cells, cytochrome c was sequestered
exclusively in mitochondria (Figures 4A, B, and 5, lane
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3). Consistent with the essential role of cytochrome c in
the autocatalytic cleavage of caspase 9 to produce the
p35 fragment, in dsRNA-treated HeLa cells there was
a detectable release of cytochrome c from mitochondria
into the cytosol (Figure 4, compare lanes 1 and 13).
Bax and Bak exert redundant roles in mediating cy-
tochrome c release in apoptosis.41 As expected,43–46 in
untreated cells, we observed Bak exclusively in the Tri-
ton X-100-resistant fraction (Figure 4, lane 3). Follow-
ing dsRNA treatment, a redistribution of Bak toward
the Triton X-100-soluble fraction was detected (Figure 4,
compare lanes 2 and 14). At the same time, Bax, which
is a mainly cytosolic protein [45 and see (Figures 4A, B,
and 5, lane 1)] displayed, in response to dsRNA treat-
ment, a tendency toward increased association with the
surface of mitochondria 42 at 3 h post treatment with
dsRNA (Figure 4A, compare lanes 1, 2, 13, and 14),
followed by an apparent degradation at 6 h post treat-
ment (Figure 4B, compare lanes 1, 2, 13, and 14). Fi-
nally, we investigated the effects of dsRNA on the cas-
pase 8 substrate Bid. The full size Bid protein displayed
cytosolic distribution in untreated cells (Figure 4, lane
1). In response to dsRNA, the steady-state levels of full
size Bid declined in a time-dependent fashion, (Figure 4,
compare lanes 1 and 13). With the antibody available,
we were unable to detect the p15 truncated fragment
of Bid (tBid) that results from the cleavage of the full
size protein by caspase 8 and that translocates to the sur-
face of mitochondria.39,40 However, the disappearance of
full size Bid from the dsRNA-treated cells was unlikely
to result from the mere dsRNA-induced inhibition of
protein synthesis and high turnover rate of the protein,
since CHX, a potent protein synthesis inhibitor, failed to
trigger any detectable changes in Bid levels even at 6 h
post addition (Figure 4B, lane 4). We concluded, there-
fore, that following the activation of caspase 8 in dsRNA-
treated HeLa cells, the pro-apoptotic Bcl-2 family mem-
bers Bid, Bax, and Bak are mobilized to trigger the release
of cytochrome c from mitochondria, thus providing the
potential mechanism for the autocatalytic processing of
caspase 9.
A role for the inhibition of protein synthesis
in accelerating the execution of apoptosis
downstream of, and including, the activation
of caspase 8
Does the dsRNA-induced inhibition of protein synthe-
sis play a role in the rapid dsRNA-induced apoptosis?
We have previously demonstrated that inhibition of pro-
tein synthesis by inhibitors of translation triggers, on its
own, apoptotic cell death in HeLa cells.6 This apoptotic
response, however proceeds with significantly delayed
kinetics compared to the cell death triggered by dsRNA
(Figure 1 and ref. 6; therefore, we consider it highly un-
likely that inhibition of translation alone could account
for the rapid apoptosis triggered by dsRNA. We spec-
ulated, however, that the inhibition of protein synthe-
sis might play a role in accelerating the execution of
apoptosis triggered by the activation of an apical cas-
pase (such as caspases 8 or 9). To test this possibility,
we activated caspase 8 with CH11 (a Fas-activating anti-
body that does not, on its own, cause a significant in-
hibition of [3H]-leucine incorpopration in HeLa cells;
not shown) in the absence or in the presence of CHX.
CHX alone was inefficient in triggering any of apop-
totic steps we have investigated (e.g., activation of cas-
pase 8, mobilization of Bid, Bax, and Bak, release of
cytochrome c, or cleavage of PARP) for up to 6 h post
addition (Figure 4, lanes 4–6). The CH11-treated cells
displayed little activation of caspase 8, mobilization of
Bid, Bax, and Bak, and release of cytochrome c at 3 h
post addition (Figure 4A, lanes 7–9), but displayed a
detectable activation of these apoptotic pathways at 6j
post addition (Figure 4B, lanes 7–9). However, both 3
and 6 h following the combined treatment of cells with
both CH11 and CHX, a dramatic acceleration of the ac-
tivation of caspase 8 was observed (Figure 4, lanes 10–
12). Subsequently, CHX increased the CH11-induced
mobilization of Bid, Bax, and Bak, the release of cy-
tochrome c, and the cleavage of PARP (Figure 4, compare
lanes 7–9 to lanes 10–12). Overall, the apoptotic po-
tential of CH11 in the presence of CHX was indistin-
guishable from the one displayed by dsRNA alone (Fig-
ure 4, compare lanes 10–12 to lanes 13–15). CHX was
able to accelerate the dsRNA-induced apoptosis as well,
but to a much lesser degree than the effect of CHX on
the CH11-induced apoptosis (Figure 4, compare lanes
13–15 to lanes 16–18), suggesting that CHX acceler-
ates a process that dsRNA alone is capable of initiat-
ing through the dsRNA-induced inhibition of protein
synthesis.
Surprisingly, we discovered that the acceleration of
apoptosis caused by inhibition of protein synthesis is not
invariably operational, but rather depends on the nature
of the specific apoptotic stimulus. To this end, we inves-
tigated the degree to which CHX affected the cell death
triggered by ultraviolet-B (UVB) radiation. We observed
that, within 6 h post treatment, UVB triggered typical
apoptotic features in HeLa cells, including the process-
ing of caspase 8 to p43/p41 (but not to p18), translo-
cations of Bax and Bak, release of cytochrome c, and
cleavage of PARP (Figure 5, lanes 4–6). However, the
presence of CHX failed to accelerate, specifically, the pro-
cessing of caspase 8 to p18 and, in general, the overall pro-
gression of apoptosis (Figure 5, compare lanes 4–6 to lanes
7–9).
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Figure 5. Mobilization of Bid, Bax, and Bak, and release of cy-
tochrome c from mitochondria in response to UV-B. Where in-
dicated, HeLa cells were treated for 6 h with UV-B [2400 J/m2;
the mode of UV-B irradiation has been described previously in
refs72,73] or a combination of UV-B and CHX (25 µg/ml). The cells
were processed and each fraction was designated as in Figure 4.
Immunoblot analyses depicting the appearance of Bid, Bax, Bak,
and cytochrome c in each fraction, are presented. The membranes
were re-probed for caspase 8 and PARP to monitor for the overall
degree of apoptosis after each treatment. Results are interpreted
in the text.
Recapitulation of the dsRNA-triggered apoptotic
pathways by infection with encephalomyocarditis
virus (EMCV)
We investigated the appearance of apoptosis after a bona
fide infection with virus. Both at 8 and at 20 h after the
infection of HeLa cells with EMCV, we observed pro-
cessing of caspases 8, 9, 3, 7, and appearance of DE-
VDase activity, as assessed by the cleavage of PARP
(Figure 6). Translocations of Bax and Bak, and release
of cytochrome c from mitochondria were also detected
(not shown). In conclusion, the apoptotic features dis-
played by HeLa cells after either introduction of syn-
thetic dsRNA or infection with EMCV were identi-
cal, with the exception that EMCV-induced apoptotic
phenotype required longer times to develop than the
dsRNA-induced apoptosis. This finding is consistent with
the longer times required for the accumulation of viral
dsRNA after infection compared to the rapid accumu-
lation of intracellular synthetic dsRNA introduced via
lipofection.
Figure 6. Apoptosis triggered by EMCV infection. HeLa cells
were infected, where indicated, with EMCV as described in Ex-
perimental Procedures. At the indicated times (h, hours), the cells
were harvested, processed for immunoblot analyses, and ana-
lyzed as in Figure 1.
Discussion
Key role of caspase 8 in initiating
dsRNA-induced apoptosis
Using kinetic analysis (Figure 1) and specific peptide
inhibitors of caspases (Figure 2) we have identified cas-
pase 8 as a key initiator of dsRNA-induced apoptosis in
HeLa cells. Our findings are in agreement with those of
Balachandran et al. who have previously reported the acti-
vation of caspase 8 in dsRNA-treated mouse fibroblasts.5
The direct activation of caspase 3 by caspase 8 is supported
by the cleavage of caspase 3 at a consensus caspase 8 cleav-
age sequence (IETD175) in the procaspase 3 molecule and
by the ability of zIETDfmk to suppress efficiently the
dsRNA-induced processing of procaspase 3 to p20 and,
subsequently, to p19/p17 (Figure 2A). The indirect acti-
vation of effector caspases by caspase 8 via a mitochondria-
dependent pathway appears to involve the translocation
of Bid, Bax, Bak, and cytochrome c (Figure 4), presum-
ably leading to the activation of caspase 9. We cannot rule
out the possibility that a signaling event that does not in-
volve caspase 8 and Bid cleavage may trigger the release
of cytochrome c from mitochondria and contribute to the
overall activation of caspase 9. However, the substantial
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Figure 7. A model for the apoptotic action of viral dsRNA. The major dsRNA-activated apoptosis signaling pathways identified in this
work are depicted. OAS, 2′ -5′ oligoadenylate synthase.
inhibition of the dsRNA-induced activation of caspase
9 in the presence of the caspase 8 inhibitor zIETDfmk
(Figure 2A) suggests that the major pathway contributing
to the bulk of active caspase 9 is dependent on activation
of caspase 8 (Figure 7).
An alternative pathway for the activation
of caspase 9
The “classical” pathway of cytochrome c-dependent au-
tocatalytic activation of procaspase 9 results from the
autocleavage at PEPD315 to produce a p35 fragment.36
We have identified in dsRNA-treated (or EMCV-infected)
HeLa cells an alternative pathway to the activation of cas-
pase 9 that appears to precede the cleavage at PEPD315.
This pathway involves the caspase 3-mediated processing
of procaspase 9 at DQLD330 to yield a p37 fragment of
caspase 9 (Figures 1, 2, and 6).
The experimental evidence supports the notion that
the p37 fragment of caspase 9 is produced exclusively by
the DEVDase caspase 3. First, the dsRNA-induced pro-
cessing of caspase 9 is blocked by the DEVDase inhibitor
zDEVDfmk. Second, dsRNA was unable to trigger the
appearance of p37 in MCF7 cells (that lack caspase 3 but
contain caspase 7; Figure 3). According to the model pro-
posed by Srinivasula et al.,54 the BIR3 region of XIAP
binds to the N-terminus of the small subunit of caspase
9, thereby inhibiting it. However, the binding of (and
inhibition by) XIAP occurs only if the N-terminal ATPF
motif of the small subunit has been exposed by the au-
tocleavage at PEPD315. Srinivasula et al. have found that
XIAP cannot not bind (and cannot inhibit) the uncleaved
zymogen, procaspase 9.54 We suggest that the cleavage
of procaspase 9 at DQLD330 may create an alternative
version of the small subunit of caspase 9 that lacks an
exposed N-terminal ATPF motif, which now remains as
part of the large p37 subunit. This alternative version of
the processed procaspase 9 may be resistant to inhibition
by XIAP and perhaps other BIR3-containing IAPs. Fur-
ther experiments are necessary to test this hypothesis and
to determine if cells that display this alternative form of
caspase 9 cleavage display also an increased sensitivity to
the pro-apoptotic effects of dsRNA.
The role of dsRNA-induced inhibition of protein
synthesis in the cytotoxicity of dsRNA
The best-characterized effect of dsRNA on cells is the
inhibition of protein synthesis. In response to dsRNA,
PKR55 phosphorylates the α-subunit of the eukaryotic
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Figure 8. Proposed sequence of caspase-activating events during dsRNA-induced apoptosis in HeLa cells. Four major steps are
identified (©1 –©4 ). ©1 . In the first step, procaspase 8 undergoes an autocatalytic processing and activation by proteolysis at VETD
and/or LEMD motifs between the large and the small subunits. This step is strongly suppressed by zVADfmk (pan-caspase inhibitor)
and zIETDfmk (caspase 8 inhibitor), and to a significantly lesser extent by zLEHDfmk (caspase 9 inhibitor) or zDEVDfmk (DEVDase
inhibitor). The further processing of caspase 8 to remove the prodomain is delayed, inefficient (Figure 1), and inhibited by all caspase
inhibitors used (Figure 4). The inefficient processing of the prodomain is likely to result from the strongly non-consensus nature of the
available cleavage sites [TISD and REQD51]. ©2 . In the second step, procaspase 3 is processed by caspase 8 (inhibition by zIETDfmk,
Figure 4A) at the IETD sequence between the large and the small subunits. Further cleavage involves the autocatalytic (inhibited by
zDEVDfmk) generation of p19 and p17 (presumably via cleavages at NSVD and ESMD). ©3 . In the third step, procaspase 9 is processed
by caspase 3 to the p37 (prodomain + large subunit) and the p10 small subunit at DQLD. ©4 . In the fourth step, p37 (and/or procaspase
9) is further processed to p35 by an autocatalytic cleavage at PEPD. The RPVD sequence located between the prodomain and the
large subunit of caspase 9 should be prohibitive for cleavage due to the presence of an arginine residue at P4 position.51 This is the
likely reason for the lack of observable prodomain cleavage in the case of caspase 9 [36 and this work]. For all steps, ProD indicates the
prodomain of a respective (pro)caspase. Arrowheads indicate cleavage and blunted lines indicate inhibition of a cleavage by a respective
inhibitor.
translation initiation factor 2 (eIF-2α),56 thereby greatly
reducing the initiation of translation.57 The 2′-5′ oligoad-
enylate synthase/RNase L system is composed of a
family of dsRNA-dependent enzymes known as 2′-5′
oligoadenylate synthases58 and the dormant cytosolic ri-
bonuclease L (RNase L).59 2′-5′ oligoadenylate-activated
RNase L cleaves diverse RNA substrates, including
18S and 28S rRNA, thereby inhibiting cellular protein
synthesis.3,60,61 We have previously shown that fibrob-
lasts from mice nullizygous for both PKR and RNase L
alleles are unable to inhibit protein synthesis when chal-
lenged with dsRNA,3 thereby demonstrating that these
two enzymes are both required and sufficient for the trans-
lational inhibition caused by dsRNA.
Both PKR5,9,48,62–65 and RNase L66–70 have been
implicated in mediating virus-induced apoptosis.
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Considering the role of both PKR and RNase L in inhibit-
ing protein synthesis, one obvious candidate for a PKR-
and/or RNase L-induced death signal is the impaired pro-
cess of translation. Although the inhibition of protein syn-
thesis can ultimately lead to the apoptotic death of cells,6
perhaps in part by preventing the synthesis of short-lived
pro-survival molecules, the results presented in Figure 4B
demonstrate that the mere inhibition of protein synthesis
is clearly unable to account for the rapid dsRNA-induced
apoptosis. For example, cycloheximide was unable to trig-
ger the activation of caspase 8 in HeLa cells for up to 6 h,
despite the complete inhibition of translation. The re-
sults presented in Figure 4 have shown that the Fas- or
dsRNA-induced activation of caspase 8 was accelerated by
the inclusion of CHX in the medium. The steady-state
levels of the anti-apoptotic short form of FLIP (FLIPS),
an inhibitor of caspase 8 activation, have been shown
to decrease in response to CHX-mediated translational
inhibition,71 making the disappearance of FLIPS one pos-
sible mechanism for the increased activation of caspase 8
under conditions of decreased protein synthesis. However,
using two independent antibodies that recognize cFLIPS,
we have failed to detect a significant decrease in expres-
sion of the FLIPs in response to CHX (not shown). Future
work is required to elucidate the mechanisms by which
inhibition of protein synthesis contributes to activation
of caspase 8 and whether the virus-instigated inhibition
of translation by PKR and RNaseL collaborates with cas-
pase 8-directed activation of the apoptotic machinery to
promote the death of virus-infected cells.
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